Companies /Healthcare

Insulet Corporation

NASDAQ: PODD Medical Devices
$145.29
▼ $7.19 (−4.72%) today
Markets closed · 7:17pm ET

24/7 Wall St. View

PODD at a Glance

Valuation
Market cap
$10.6B
P/E ratio
24.9
Profitability
Revenue (TTM)
$3.2B
Profit margin
13.4%
EPS (TTM)
$6.12
Price
52-week range
$126 – $355
24/7 target
$188.34
Street target
$178.57

Headquartered in Acton, MA Fiscal year ends December NASDAQ: PODD insulet.com

About Insulet

Insulet Corporation (NASDAQ: PODD) is a medical device company focused on tubeless insulin pump technology through its Omnipod platform. The Omnipod Insulin Management System uses a wearable, tubeless, disposable Pod that delivers up to three days of non-stop insulin without the user needing to see or handle a needle.

Its flagship Omnipod 5 Automated Insulin Delivery System integrates with continuous glucose monitors, including Abbott's FreeStyle Libre 3 Plus in a growing number of international markets. The system manages blood sugar without multiple daily injections or fingersticks, and it can be controlled from a compatible smartphone in the U.S. or from the Omnipod 5 Controller. Insulet also offers Omnipod Discover, an engagement platform that gives people with diabetes and their healthcare professionals personalized insights and decision support.

Insulet serves both type 1 and type 2 diabetes populations. Its revenue comes mainly from Omnipod sales in the U.S., which accounted for $570.4 million in Q3 2026, and in international markets, which accounted for $266.2 million. A smaller Drug Delivery business adapts the Pod for subcutaneous delivery of non-insulin drugs.

The company's pipeline includes Omnipod 6, now in the STRIVE2 trial, and fully closed-loop automated insulin delivery for type 2 diabetes, now in the EVOLVE pivotal study. Updated

Latest Activity

PODDInsulet
Q3 2026
EPS
$1.99
est $1.59+25.4%
Revenue
$842M
est $833M+1.1%

International Omnipod sales jumped 31.7%, enough for Insulet to lift full-year constant-currency revenue growth guidance and double its margin expansion target. The board also approved a buyback, with part of it planned for the fourth quarter.

Quarterly EPS — reported vs estimate

PODD Coverage

Frequently Asked Questions

What does Insulet do?

Insulet Corporation (NASDAQ: PODD) is a medical device company focused on tubeless insulin pump technology through its Omnipod platform. The Omnipod Insulin Management System uses a wearable, tubeless, disposable Pod that delivers up to three days of non-stop insulin without the user needing to see or handle a needle.

What is the PODD stock price target?

24/7 Wall St.'s 12-month price target for PODD is $188.34, rated Buy. The Wall Street consensus target is $178.57. PODD price prediction →